Navigation Links
Blood Cancer Advances May Improve Survival

SATURDAY, Dec. 4 (HealthDay News) -- Advances in the treatment of blood cancers offer new hope for increased survival, according to two studies scheduled to be presented at the American Society of Hematology meeting Saturday in Orlando, Fla.

Results from one study suggest that treating multiple myeloma patients with zoledronic acid can improve survival, while another group of researchers are scheduled to report on their progress in treating a particularly aggressive form of acute lymphoblastic leukemia (ALL).

Zoledronic acid, a type of bisphosphonate, is given to myeloma patients to bolster bone health and reduce the risk for fracture and bone pain that are a common feature of the disease.

Although prior research has suggested that zoledronic acid (brand names include Zometa and Reclast) may have a broader anti-cancer effect, the current study finds that a well-tolerated regimen of the drug can reduce the risk of death among myeloma patients.

The study is published in the Dec. 4 online edition of The Lancet.

"These data add to growing clinical evidence supporting anti-cancer benefits with zoledronic acid in patients with newly diagnosed cancers," the study team, led by Gareth J. Morgan from the Institute of Cancer Research in London, said in a journal news release.

The authors base their conclusions on work with 1,960 multiple myeloma patients, about half of whom were treated with zoledronic acid in combination with either intensive or non-intensive chemotherapy. The other half received clodronic acid (another type of bisphosphonate) and equivalent chemotherapy regimens.

Treatments continued for an average of one year, while further follow-up was conducted for nearly four years.

The zoledronic acid patients experienced 16 percent fewer fatalities (and saw their life expectancy extended by 5.5 months) compared with those on the alternative treatment program, the authors found.

The team also noted that progression-free survival rates came in 12 percent better among those given zoledronic acid. Chemotherapy intensity did not appear to affect fatality and survival outcomes.

However, in an accompanying editorial, Dr. S. Vincent Rajkumar of the Mayo Clinic in Rochester, Minn., said high-potency bisphosphonates can lead to serious complications. He recommends further study to determine the appropriate dose and treatment time.

The second study scheduled for presentation Monday at the hematology meeting reports promising results for a regimen of imatinib (Gleevec) in patients with Philadelphia chromosome-positive (Ph+) ALL, a form of acute lymphoblastic leukemia that progresses rapidly and has a poor prognosis.

The team, led by Adele K. Fielding from University College London, tracked treatment outcomes of about 440 patients. The first group of Ph+ patients was treated solely with chemotherapy and stem cell transplants before imatinib became available in 2003. Post-2003, a second group was given 600 milligrams daily of imatinib following two rounds of chemotherapy. And in 2005, a third group received an earlier round of imatinib in conjunction with a second round of chemotherapy. The imatinib patients continued their drug regimen for two years.

After three years of follow-up, Fielding and colleagues found that each successive approach yielded better results. In the pre-imatinib group, the survival rate was 25 percent. By contrast, survival increased to 34 percent among the imatinib post-chemotherapy group and to 48 percent among the with-chemotherapy group.

The authors concluded that early treatment with imatinib can optimize long-term survival.

The findings of both studies "make sense" to Dr. Marshall Lichtman, a professor of medicine and biochemistry and biophysics at the University of Rochester Medical Center in Rochester, N.Y.

"In regard to myeloma, the last five to 10 years have seen a striking improvement in survival and well-being of patients with advances in therapy. And it's been known for some time that bisphosphonates have an effect not just on bone health but on the myeloma cells themselves," he noted.

"It's conceivable that different forms of bisphosphonates may have the same effect in terms of ameliorating bone disease but one may have a more suppressive effect on the myeloma cells," explained Lichtman, formerly executive vice president of research and medical programs for the Leukemia & Lymphoma Society. "So this study points to zoledronic acid as being more advantageous."

As for imatinib, the researchers "show impressive outcomes, and document striking differences in survival rates, that speak to the importance of using imatinib early," he said.

Because these studies were presented at a medical meeting, the findings should be viewed as preliminary until they are published in a peer-reviewed journal.

More information

For more on multiple myeloma, visit the Leukemia & Lymphoma Society.

-- Alan Mozes

SOURCES: Marshall Lichtman, M.D., professor of medicine and biochemistry and biophysics at the University of Rochester Medical Center, Rochester, N.Y.; news release, The Lancet, Dec. 4, 2010; news release, American Society of Hematology, Dec. 4, 2010

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inflammatory Bowel Ups Risk for Blood Clots
2. Bowel disease link to blood clots
3. Local Blood Supply Impacted by Wednesdays Severe Snow Storm
4. PERSONALABS Offers Discounted Healthy Heart Online Blood Tests in February
5. China Cord Blood Corporation Warrant Registration Statement Declared Effective by SEC
6. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
7. Bilberry Seems to Act Against Blood Sugar
8. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
9. UCR researcher identifies mechanism malaria parasite uses to spread in red blood cells
10. NHLBI, CDC launch surveillance and research program for inherited blood diseases
11. IOM report declares high blood pressure a neglected disease
Post Your Comments:
Related Image:
Blood Cancer Advances May Improve Survival
(Date:11/30/2015)... ... November 30, 2015 , ... It’s inevitable that everyone ... member, close friend, or animal pass away, death lives among us. It is your ... Coming from a family of 11 children, author T Sky understands that she may ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... IL (PRWEB) , ... November 30, 2015 , ... The ... an emerging pharmaceutical company. Because it is so important to this key industry segment, ... Factors in your IND Filing” on December 4th at 11am EST. , Federal law ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, Inc. ... Surgical Mesh technology for soft tissue repair in the US via Insightra’s national ... resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 months ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... & Laser Center is one of a select few plastic surgeons in the ... non-surgical fat removal. , SculpSure™ is the world’s first heat-induced laser treatment for ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... -- Booth #4303 – The Imaging Components business of Varian ... array of products in a new booth (#4303) at the ... America in Chicago this ... components "At the Heart of Imaging." Products will include a ... Claymount brand, and computer-aided diagnostic software from MeVis as well ...
(Date:11/30/2015)... -- Hanger, Inc. (NYSE: HGR ) (the "Company") today ... its previously announced consent solicitation (as amended and restated, ... amount 7⅛% Senior Notes due 2018 (the "Notes") to ... pursuant to the Consent Solicitation, (ii) the proposed increased ... date of the Consent Solicitation.    ...
(Date:11/30/2015)... , Nov. 30, 2015   VolitionRx Limited (NYSE ... diagnostic tests for a broad range of cancer types and ... LD Micro Conference, which will be held December 1 - 3 ... from VolitionRx will be David Kratochvil , Chief Financial ... of Investor Relations. ® blood-based tests for ...
Breaking Medicine Technology: